Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lateral flow test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Lateral flow test. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2016-002399-28 Sponsor Protocol Number: RAP-ALS Start Date*: 2017-07-14
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA
    Full Title: Rapamycin (Sirolimus) treatment for amyotrophic lateral sclerosis
    Medical condition: definite or probable ALS
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003479-20 Sponsor Protocol Number: 2011/433 Start Date*: 2013-04-15
    Sponsor Name:Handkirurgiska kliniken, Universitetssjukhuset Örebro
    Full Title: Lateral humerus epicondylitis- a clinical, muscle morpological, muscle metabolical and functional evaluation of a new model for treatment.
    Medical condition: Chronic lateral humerus epiconcylitis
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004863 10024032 Lateral epicondylitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001989-38 Sponsor Protocol Number: IMCRELA Start Date*: 2021-07-08
    Sponsor Name:Facultad de medicina y ciencias de la salud de la Universidad Católica de Valencia
    Full Title: IMPACT OF THE COMBINED TREATMENT OF THE LIPOSOMATED POLYPHENOLS CÚRCULA AND RESVERATROL® WITH DUTASTERIDE, IN THE CLINICAL IMPROVEMENT OF PATIENTS WITH ALS TREATED WITH RILUZOLE
    Medical condition: Amyotrophic Lateral Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-003244-27 Sponsor Protocol Number: PANORAMIC-Norway Start Date*: 2023-04-11
    Sponsor Name:Helse Bergen HF
    Full Title: PAxlovid loNg cOvid-19 pRevention triAl with recruitMent In the Community in Norwayy
    Medical condition: COVID-19 SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004848 10084355 COVID-19 virus test positive LLT
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002742-20 Sponsor Protocol Number: CL2-16257-101 Start Date*: 2013-03-20
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Effect of ivabradine versus placebo on cardiac function, exercise capacity, and neuroendocrine activation in patients with Chronic Heart Failure with Preserved left ventricular Ejection Fraction A...
    Medical condition: Heart failure with preserved left ventricular ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PT (Completed) IT (Completed) DE (Completed) BE (Completed) GB (Completed) NL (Completed) ES (Completed) CZ (Completed) AT (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2011-000805-27 Sponsor Protocol Number: MEIN/10/Ran-Did/001 Start Date*: 2012-10-23
    Sponsor Name:Menarini International Operations Luxembourg S.A., Avenue de la Gare, 1611 Luxembourg, Luxembourg
    Full Title: Effect of Ranolazine in Heart Failure Patients with Preserved Ejection Fraction
    Medical condition: Heart failure patients with preserved ejection fraction (HFpEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10019280 Heart failures HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006340-60 Sponsor Protocol Number: OPTUK RFCP PRO002.04 Start Date*: 2007-03-14
    Sponsor Name:OptiNose UK Ltd
    Full Title: A Double Blind, Randomised, Parallel Group, Placebo-Controlled Study to Investigate the Efficacy and Tolerability of Intranasal Fluticasone Propionate Delivered by the Optinose Device in Adult Pati...
    Medical condition: treatment of bilateral nasal polyposis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004132-22 Sponsor Protocol Number: NPH-01 Start Date*: 2021-01-20
    Sponsor Name:Uppsala University Hospital
    Full Title: Double-blind randomized acetazolamide trial in normal pressure hydrocephalus
    Medical condition: Normal pressure hydrocephalus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10020510 Hydrocephalus acquired LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000655-36 Sponsor Protocol Number: 80684 Start Date*: 2023-04-06
    Sponsor Name:Amsterdam UMC
    Full Title: Evaluation of GeranylGeranylAcetone in heart failure with preserved ejection fraction
    Medical condition: Heart Failure with preserved ejection fraction.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002101-25 Sponsor Protocol Number: FDA02_AIM3 Start Date*: 2020-09-14
    Sponsor Name:HEALTH – Institute for Biomedicine and Health Sciences, JOANNEUM RESEARCH Forschungsgesellschaft mbH
    Full Title: A SINGLE CENTER, OPEN-LABEL, CLINICAL STUDY TO EVALUATE THE ABILITY OF DERMAL OPEN FLOW MICROPERFUSION (DOFM) FOR BIOEQUIVALENCE TESTING OF TOPICALLY APPLIED DICLOFENAC SODIUM PRODUCTS IN HEALTHY S...
    Medical condition: Healthy Volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002560-73 Sponsor Protocol Number: SWITCH_ON Start Date*: 2022-09-01
    Sponsor Name:Erasmus MC
    Full Title: SWITCH ON: Analysing the immunogenicity of additional booster vaccinations in healthcare workers.
    Medical condition: To study the necessity to boost healthcare workers (which arre representative for the dutch population) with a COVID vaccin by measuring the immunogenicity at 7 days and 28 days..
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-006997-27 Sponsor Protocol Number: CRAD001M2301 Start Date*: 2011-06-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled study of RAD001 in the treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC)
    Medical condition: This study will evaluate the antitumor activity of RAD001 versus placebo in patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC).
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) GB (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-022725-16 Sponsor Protocol Number: RE-0240/2010/EN Start Date*: 2012-03-30
    Sponsor Name:FRANCISCO JOSE MORALES PONCE
    Full Title: INTRACORONARY ADMINISTRATION OF TENECTEPLASE VERSUS ABCIXIMAB AS ADJUNCTIVE TREATMENT DURING PRIMARY ANGIOPLASTY IN ACUTE MYOCARDIAL INFARCTION OF ANTERIOR LOCATION
    Medical condition: ACUTE MYOCARDIAL INFARCTION
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10000894 Acute myocardial infarction, of anterolateral wall, initial episode of care LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004039-64 Sponsor Protocol Number: MYK-461-007 Start Date*: 2019-11-14
    Sponsor Name:MyoKardia, Inc.
    Full Title: A Long-term Safety Extension Study of Mavacamten (MYK-461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)
    Medical condition: Hypertrophic Cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PT (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-018289-21 Sponsor Protocol Number: EndoIGA2010 Start Date*: 2010-02-25
    Sponsor Name:Insitute of Endocrinology
    Full Title: Clinical, laboratory and ultrasound markers for the prediction of the response on the pulse-dose treatment by intravenous glucocorticoids in patients with endocrine orbitopathy
    Medical condition: active severe endocrine orbitopathy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066617 Graves' ophthalmopathy worsened LLT
    12.1 10014702 Endocrine exophthalmos LLT
    12.1 10015684 Exophthalmos endocrine LLT
    12.1 10043787 Thyrotoxic exophthalmos LLT
    12.1 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002530-17 Sponsor Protocol Number: D7220C00001 Start Date*: 2021-07-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Both Previously Vaccinated and Unvaccinated Adults to Determine the Safety and Immunogenicity of AZD28...
    Medical condition: SARS-COV-2 infection (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001036-25 Sponsor Protocol Number: UNI91103-201 Start Date*: 2021-06-01
    Sponsor Name:UNION therapeutics A/S
    Full Title: A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UNI91103 INTRANASAL ADMINISTRATION IN ADULTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC COVID-19
    Medical condition: Covid-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-000641-33 Sponsor Protocol Number: PAX Start Date*: 2022-04-21
    Sponsor Name:Fundació FLS de Lluita contra la Sida, les Malalties Infeccioses i la Promoció de la Salut i La Ciència
    Full Title: Plasma Exchange Therapy for Post- COVID-19 Condition: A Pilot, Randomized Double-Blind Study
    Medical condition: Post-Acute-Covid-19 Syndrome
    Disease: Version SOC Term Classification Code Term Level
    24.0 10021881 - Infections and infestations 10085503 Post-acute COVID-19 syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000240-26 Sponsor Protocol Number: PC_ASP_002 Start Date*: 2019-05-17
    Sponsor Name:Pulmocide Ltd
    Full Title: An open-label, pilot study to assess safety, tolerability, pharmacokinetics and effects of inhaled PC945 in the pre-emptive treatment of Aspergillus fumigatus colonisation in lung transplant recipi...
    Medical condition: Pre-emptive treatment of Aspergillus fumigatus colonisation in lung transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10059259 Pulmonary aspergillosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000410-22 Sponsor Protocol Number: U1111-1140-6242 Start Date*: 2015-10-27
    Sponsor Name:The Cardiovascular MR Group, Dept. 2011, Rigshospitalet
    Full Title: Influence of liraglutide on diastolic cardiac function and myocardial perfusion as determined by magnetic resonance imaging in patients with type 2 diabetes: a double-blind randomized parallel-grou...
    Medical condition: Type 2 diabetes mellitus and diastolic heart faliure
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10069211 Diastolic heart failure LLT
    18.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 12:38:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA